About the Company
Expanding immune system stimulation to revolutionize vaccines… That is Inovio’s (NYSE MKT: INO) quest. Stimulating the body’s immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis C virus, and other chronic infectious diseases. Our synthetic vaccine technology platform is progressively showing its potential to establish a new paradigm to prevent and treat these life-altering diseases. Our growing pipeline of vaccine candidates based on this technology has now advanced to phase II clinical studies. These vaccines could potentially protect millions of people from sickness or death due to disease. At Inovio, we are playing an integral role in defining the future of medicine. We invite you to join us on our journey: as an investor, a participant in our clinical studies, a partner, or just an interested observer.
PLYMOUTH MEETING, Pa., April 24, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that it has commenced a phase 2 trial to evaluate the efficacy of VGX-3100 in patients with pre-cancerous lesions of the vulva, or vulvar...
Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial
PLYMOUTH MEETING, Pa., April 11, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) announced today preliminary results from the expanded stage of its phase I study, EBOV-001. The expanded study examined different regimens of its Ebola DNA vaccine INO-4201...
Inovio and Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP’s Ability to Induce Remission of HIV Infection and End Lifetime of Drug Therapy
PLYMOUTH MEETING, Pa., March 30, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) announced today that its academic and industry collaborators received a multi-year $6.95 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to develop...
PLYMOUTH MEETING, Pa., March 21, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) announced today the election of George Bickerstaff to its Board of Directors. Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology. He...